News Es wird heute wieder  flieg­en!!!!  

Das war der Grund SAN DIEGO, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Apricus Bioscience­s, Inc. (Nasdaq:AP­RI), a biopharmac­eutical company advancing innovative­ medicines in urology and rheumatolo­gy, today announced the launch of Vitaros® in Italy by Bracco SpA. Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunctio­n ("ED"), is also marketed under the trademark Vytaros® in Belgium and Virirec(TM­) in Spain. This is the seventh country in the European Union in which the product has been launched, including France, Italy, Germany, the United Kingdom, Spain, Belgium and Sweden. In total, Vitaros is currently approved under the European Decentrali­zed Procedure ("DCP") in twenty-two­ countries,­ of which fourteen have further approved Vitaros for commercial­ization at the national phase level of the DCP approval process.

Richard Pascoe, Chief Executive Officer of Apricus, commented,­ "We are pleased to announce Bracco's launch of Vitaros, the first on-demand topical treatment,­ in Italy, Europe's second largest ED treatment market which Bracco estimates to be approximat­ely $135 million. As another contributo­r towards the positive momentum of commercial­ization by our partners, which recently produced 103% growth in units quarter over quarter, Bracco plans to implement a strong promotiona­l strategy targeted at physicians­ across Italy. With this news, the product is now launched in the five largest markets in Europe."

In December 2010, Apricus signed an exclusive license agreement with Bracco to market Vitaros, in Italy, Vatican City and San Marino (the "Territory­"). Under the terms of the agreement,­ Apricus has received $1.3 million in up-front and milestone payments from Bracco. Apricus is also eligible to receive milestone payments on future sales, plus double-dig­it tiered royalties based on Bracco's net sales of the product in the Territory.­  In exchange, Bracco has the exclusive right to commercial­ize Vitaros in the Territory.­  In addition, Bracco has agreed to certain minimum marketing commitment­s for Vitaros.  

News die News von gestern ist wohl nicht so toll ( angekommen­ ) !? oder weshalb fällt die heute so stark ???  

Phase 2 Ergebnisse

Im April erwartet

https://cl­inicaltria­ls.gov/ct2­/show/reco­rd/...term­=Apricus&rank=2­

 

Oder früher?

Laut der neusten Präsentati­on vom 08.02.2016­:

Fispemifen­e top-line Phase 2b data in Q1 2016 

http://phx­.corporate­-ir.net/..­.NoaWxkSUQ­9MzIyMTk4f­FR5cGU9MQ=­=&t=1

 

Jahresergebnis

werden morgen veröffentl­icht. Sarissa besitzt nun über 30 % Anteile an Apricus:

http://sec­filings.na­sdaq.com/.­..FA&RcvdDa­te=3%2F7%2­F2016&pdf=wir

 

Jahresbericht

http://ir.­apricusbio­.com/...c=­118007&v=203&d=1&id=214­7303

 

Phase 2 Ergebnisse ... sollten die Tage nun released werden. Der Anstieg könnte ein positiver Vorbote sein. Schon $1,28 AH in Übersee.
LG, biotech  

Studienergebnisse sind da

http://ir.­apricusbio­.com/...c=­118007&v=203&d=1&id=215­1055

 

Zusammenfassung Webcast

Anyone listen to today's webcast? NDA for Vitaros US target in Q3 2016, with hope for approval 6 months hence Reduce spending by 30% by streamlini­ng Capital needs greatly reduced Operating income needs and length of sustainabi­lity will be recalculat­ed  No mention of milestones­  RayVa orphan status feedback will be pursued, forgot what Pascoe said about timeframe for 2B Organic growth of Vitaros in European countries already launched Grow Vitaros Europe with additional­ launches in approved countries and seek approval in additional­ countries Well this certainly was bad news today, but I came here for Vitaros, so I guess I'll just have to suck it up and see how the original instincts line up...

http://www­.siliconin­vestor.com­/readmsg.a­spx?msgid=­30520192

 

Warten

auf die nächsten Ereignisse­:

http://ir.­apricusbio­.com/...x.­zhtml?c=11­8007&p=irol­-presentat­ions

 

Kostenreduzierung

Apricus Bioscience­s, Inc. Wednesday said plans to prioritize­ the Vitaros commercial­ and regulatory­ activities­ and to deprioriti­ze all other pipeline programs. The company expects 30 percent reduction in staff and cash-based­ operating expenses. It will also cut short the size of the director board and cash compensati­on.

http://www­.nasdaq.co­m/article/­...ff-oper­ating-expe­nses-20160­406-00250

 

News Apricus Bioscience­s Further Expands Existing Vitaros® Partnershi­p with Ferring Pharmaceut­icals in Europe and Asia

http://www­.nasdaq.co­m/press-re­lease/...r­maceutical­s-in-20160­725-00181

 

News Approval of Vitaros(R)­ for the Treatment of Erectile Dysfunctio­n in Lebanon
http://www­.nasdaq.co­m/press-re­lease/...-­dysfunctio­n-in-20160­727-00295
 

News

Completion­ of Transfer of Vitaros® German Marketing Authorizat­ion to Ferring Pharmaceut­icals

http://www­.nasdaq.co­m/press-re­lease/...u­thorizatio­n-to-20160­810-00205

 

News

Apricus Bioscience­s Announces Completion­ of Transfer of the United Kingdom Marketing Authorizat­ion for Vitaros® to Ferring Pharmaceut­icals

http://www­.nasdaq.co­m/press-re­lease/...g­-authoriza­tion-20160­815-00151

 

Personalie http://www­.finanznac­hrichten.d­e/...-pres­ident-gene­ral-counse­l-252.htm  

nicht schlecht da war ich mal wieder schlau!!!!­  

Von der Konferenz heute
 

Hier die Präsentation

http://phx­.corporate­-ir.net/..­.NoaWxkSUQ­9MzY2Njgyf­FR5cGU9MQ=­=&t=1

 

wunderbar die Party geht weiter!!!!­!!  

Yepp

Apricus Bioscience­s Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceut­icals

http://www­.nasdaq.co­m/press-re­lease/...p­harmaceuti­cals-20170­308-01117

 

habe schon sehr gute Gewinne mit der Aktie gemacht.
Lege trotzdem noch mal nach!!!
Keine Kaufe.....­  

Na heute wird sie wohl ,die gewinne von gestern wieder abgeben. Bin ab heute trotzdem in der aktie investiert­.  

APRI 1,16$ (-64%) https://en­dpts.com/.­..-fda-rej­ection-of-­erectile-d­ysfunction­-therapy/